Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential

The findings, presented astatine the EULAR 2026 Congress and published successful the New England Journal of Medicine, item the drug's imaginable arsenic a first-line therapy. The trial, the largest ever conducted for this disease, showed that implicit 73% of treated patients remained flare-free done 52 weeks with a information illustration comparable to the placebo.

Following these palmy results, Zenas BioPharma Inc. (NASDAQ:ZBIO) submitted a Biologics License Application to the FDA successful May. The institution continues to beforehand its objective pipeline, with further information expected aboriginal this twelvemonth from its Phase 2 proceedings for systemic lupus erythematosus.

Zenas BioPharma Inc. (NASDAQ:ZBIO) is simply a clinical-stage institution focused connected processing transformative therapies for autoimmune diseases. Their pipeline features late-stage candidates similar obexelimab and orelabrutinib, alongside respective earlier-stage programs targeting chronic inflammatory conditions.

While we admit the imaginable of ZBIO arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey connected Google News.